Streetbeat News

Products Services

ANAB

AnaptysBio Inc (NASDAQ:ANAB) has released positive topline results from its global Phase 3 GEMINI-1 trial of imsidolimab in patients with generalized pustular psoriasis (GPP) flares. The drug met its primary endpoint, achieving rapid clearance of pustulation, erythema, and scaling through Week 4 after a single dose. The data also showed a favorable safety and tolerability profile. The company plans to present comprehensive data from GEMINI-1 and topline GEMINI-2 results at a medical meeting in H2 2024 and anticipates filing a biologics license application with the FDA by Q3 2024. ANAB shares are up 16.9% at $22.50 during the premarket session on the last check Monday.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 1:26 pm

MULN

Mullen Automotive, Inc. (NASDAQ:MULN) has appointed Marianne McInerney as Chief Strategy Officer. McInerney, who has nearly two decades of experience in the automotive and transportation industry, will focus on growth opportunities and strategic initiatives for Mullen's commercial, consumer vehicles, and governmental affairs. She will also oversee all state and federal governmental affairs for the company. Mullen recently announced several key milestones, including the delivery of its first Class 3 EV Cab Chassis Trucks and EPA certification for these trucks.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 1:04 pm

GOVX

GeoVax has received a notice of allowance for its Marburg vaccine patent, titled 'Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) And Matrix Protein (VP40)'. The patent application number is 17/584,231.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 1:01 pm

HYPR

Hyperfine, Inc. has received FDA clearance for its updated AI-powered software, which improves image quality for all Swoop System sequences. This development could potentially enhance the company's market position.

Portfolio Pulse from Bill Haddad

October 09, 2023 | 1:01 pm

ALNY

ANAB

MTEK

AnaptysBio (ANAB) announced positive top-line Phase 3 clinical trial results for Imsidolimab, causing a 29% increase in stock price. Maris-Tech (MTEK) will exhibit at Milipol Paris 2023, featuring its AI-based intelligence gathering and advanced video payload solutions, leading to a 45% stock price increase. Alnylam (ALNY) received a complete response letter from the U.S. FDA for a supplemental new drug application, causing a 7% decrease in stock price.

Portfolio Pulse from ryanfaloona@benzinga.com

October 09, 2023 | 12:54 pm

MCOM

Micromobility.com Inc. (NASDAQ:MCOM), parent company of Wheels, has announced a significant increase in subscriptions following the successful opening of its flagship Soho store. The company plans to expand its operations into Los Angeles, Seattle, Miami, and Austin. In the coming month, Wheels and its sister companies will transition their existing warehouse locations into service hubs to enhance operational efficiency and support the growing demand for micromobility subscriptions.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:48 pm

CLB

HAL

Halliburton Company (NYSE:HAL) and Core Laboratories Inc. (NYSE:CLB) have announced a strategic collaboration to compress the delivery time of comprehensive digital rock data solutions. The collaboration combines Core Lab's expertise in reservoir description and optimization technologies with Halliburton's specialization in pore-scale digital rock analysis. This will enable clients to run pore-scale simulations in parallel with physical laboratory experiments, driving the accuracy and innovation of new and existing digital rock characterization workflows.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:47 pm

TNYA

Tenaya Therapeutics presented new clinical and preclinical data from its HDAC6 inhibitor program TN-301 at the 2023 HFSA Annual Scientific Meeting. The data shows TN-301's tolerability, potential for once daily dosing, target engagement, and selectivity for HDAC6 in a Phase 1 clinical trial. Additionally, a combination of Tenaya's HDAC6 inhibitors with Empagliflozin showed additive benefits in a preclinical HFpEF model.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:42 pm

ANAB

AnaptysBio announced that imsidolimab met the primary endpoint of its global Phase 3 GEMINI-1 trial, achieving rapid clearance of GPP through Week 4 after a single dose. This news has led to a rise in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:40 pm

GROM

Curiosity Ink Media has announced a major licensing deal with Well Played Toys for its Cats Vs Pickles brand. The deal will allow Well Played Toys to manufacture and distribute Cats Vs Pickles toys globally.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:39 pm